Overall Survival Favorable With Ivosidenib for Advanced Cholangiocarcinoma With IDH1 Mutations

A final overall survival analysis found improved results and a tolerable safety profile for patients with advanced IDH1-mutated cholangiocarcinoma who received ivosidenib vs placebo.

Despite a high crossover rate, ivosidenib (Tibsovo) produced favorable survival data with a tolerable safety profile compared with placebo for patients with advanced cholangiocarcinoma with IDH1 mutations, according to final overall survival (OS) results from the phase 3 randomized ClarIDHy trial (NCT02989857) published in JAMA Oncology.1

The median OS was 10.3 months (95% CI, 7.8- 12.4) for patients in the ivosidenib group compared with 7.5 months (95% CI, 4.8- 11.1) for patients in the placebo group (HR, 0.79; 95% CI, 0.56-1.12; 1-sided P = .09) based on 150 OS events. Furthermore, the median rank-preserving structural failure time (RPSFT)–adjusted OS was 5.1 months (95% CI, 3.8-7.6) in the placebo group (HR, 0.49; 95% CI, 0.34-0.70; 1-sided P< .001).

“To our knowledge, this is the first randomized phase 3 trial demonstrating the clinical benefit of targeting the IDH1 variant for patients with advanced cholangiocarcinoma with IDH1 mutation or any other solid tumor with IDH1 mutation,” the investigators wrote.

Patients were randomized to receive either 500 mg of ivosidenib (n = 126), which was administered orally once daily for 28-day cycles or a matched placebo (n = 61). Treatment was given until disease progression, other unacceptable toxicities, pregnancy, death, consent withdrawal, loss to follow-up, or trial unblinding or ending. For patients with disease progression confirmed by radiography in the placebo group, crossover to the ivosidenib group was permitted.

Eligible patients were 18 years or older with histologically confirmed cholangiocarcinoma with an IDH1 mutation. Eligibility criteria also required documented disease progression after 1 to 2 treatments for advanced disease, an ECOG performance status of 0 or 1, an expected survival of 3 months or more, and adequate bone marrow, hepatic, and kidney function.

Although OS was a key secondary end point, it was the focus for this final analysis. Progression-free survival was the primary end point and was detailed in a previous analysis.

The median patient age was 62 years (range, 33-80 years) in the ivosidenib group and 63 years (range, 40-83 years) in the placebo group, with 65% and 61% of the ivosidenib and placebo group populations, respectively, being comprised of women.

Additional findings from the analysis indicated that the survival rate at 12 months was 43% (95% CI, 34%-51%) for patients in the ivosidenib group and 36% (95% CI, 24%-48%) for patients in the placebo group. The maximum treatment duration was 34.4 months (range, 0.1- 34.4) compared with 6.9 months (range, 0-6.9 months) for the ivosidenib and placebo groups, respectively. Moreover, the median treatment duration was 2.8 months (range, 0.1-34.4) and 1.6 months (range, 0-6.9) for the ivosidenib and placebo groups, respectively.

The most common any-grade treatment-emergent adverse effect (TEAE) for the ivosidenib and placebo groups, respectively, prior to crossover was nausea (42% vs 29%). Ascites was the most common grade 3 or higher TEAE in both treatment groups (9% vs 7%). Other common grade 3 or higher TEAEs included anemia (7% vs 0%), increased blood bilirubin level (6% vs 2%), and hyponatremia (6% vs 10%).

Serious TEAEs were observed in 34% of patients in the ivosidenib group compared with 24% of patients in the placebo group. In total, 5% of patients who were treated with ivosidenib experienced a TEAE leading to death. None of the deaths are believed to be related to treatment

“Taken together, the efficacy data and tolerable safety profile, as well as supportive quality of life data, demonstrate the clinical benefit of ivosidenib compared with placebo for patients with this aggressive disease in which there is an unmet need for new therapies,” the investigators concluded.

In August 2021, the FDA approved the use of ivosidenib in patients with previously treated IDH1 mutation–positive cholangiocarcinoma.2 The organization's decision was based on the results of the ClarIDHy trial.


  1. Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients With advanced cholangiocarcinoma with IDH1 mutation: the Phase 3 randomized clinical ClarIDHy Trial. Published online September 23, 2021. JAMA Oncol. doi:10.1001/jamaoncol.2021.3836
  2. Servier announces FDA approval of TIBSOVO® (ivosidenib tablets) in IDH1-mutated cholangiocarcinoma. News release. Servier Pharmaceuticals. August 25, 2021. Accessed September 29, 2021. https://bit.ly/3DhHGu7
Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content